772 related articles for article (PubMed ID: 16107858)
1. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
2. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
[TBL] [Abstract][Full Text] [Related]
3. Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine.
Tseng SH; Liu L; Peng S; Kim J; Ferrall L; Hung CF; Wu T-
J Biomed Sci; 2021 Sep; 28(1):63. PubMed ID: 34517865
[TBL] [Abstract][Full Text] [Related]
4. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
[TBL] [Abstract][Full Text] [Related]
5. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
[TBL] [Abstract][Full Text] [Related]
6. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
Hung CF; Calizo R; Tsai YC; He L; Wu TC
Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
[TBL] [Abstract][Full Text] [Related]
7. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
[TBL] [Abstract][Full Text] [Related]
8. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects.
Peng S; Tomson TT; Trimble C; He L; Hung CF; Wu TC
Gene Ther; 2006 Feb; 13(3):257-65. PubMed ID: 16177818
[TBL] [Abstract][Full Text] [Related]
9. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
10. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
Cheng WF; Hung CF; Chen CA; Lee CN; Su YN; Chai CY; Boyd DA; Hsieh CY; Wu TC
Vaccine; 2005 May; 23(29):3864-74. PubMed ID: 15893626
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
12. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.
Peng S; Trimble C; Alvarez RD; Huh WK; Lin Z; Monie A; Hung CF; Wu TC
Gene Ther; 2008 Aug; 15(16):1156-66. PubMed ID: 18401437
[TBL] [Abstract][Full Text] [Related]
13. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.
Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH
J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
17. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
[TBL] [Abstract][Full Text] [Related]
18. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
19. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
20. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM
Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
